Few products attract a cult-like obsession like this one. Even after being off the menu for years, true fans yearn for its return, their devotion bordering on an almost cult-like obsession. Well, they ...

GameSpot may get a commission from retail offers. Over a decade after a disastrous debut plagued with faceless NPCs and frame rate issues, Assassin's Creed Unity is rounding out its comeback story ...

Ubisoft shared its upcoming plans for the Assassin's Creed franchise today. Along with the news of a remake for its piratical entry, the game company also announced that a visual upgrade is coming for ...

Every Wednesday and Friday, TechNode’s Briefing newsletter delivers a roundup of the most important news in China tech, straight to your inbox. Sign up US real-time 3D technology company Unity ...

Feb 11 (Reuters) - Shares of videogame engine maker Unity Software dropped nearly ‌30% on Wednesday after the company ‌forecast first-quarter revenue below Wall Street expectations, signaling sluggish ...

The returning Chevy Bolt is now arriving at dealerships with seven more EPA-rated miles of range than GM originally estimated. The 2027 Bolt starts at $28,995, making it one of the cheapest U.S. EVs.

Chevrolet introduced the 2027 Bolt last fall and now they’ve revealed the electric crossover has an EPA-estimated range of 262 miles (422 km). That’s more than GM’s original estimate of 255 miles (410 ...

Unity is allegedly introducing a new annual fee for its largest Enterprise users, requiring a "minimum commitment" of $250,000 to $2 million, depending on each game's revenue. It will reportedly be ...

General Motors has heavily upgraded the Bolt, with more range and faster charging speeds. It won't be on sale for an extended time period, the automaker said in a media briefing on Thursday. Recently, ...

Unity has fixes ready to go, and Valve has released an updated version of Steam, too. Unity has fixes ready to go, and Valve has released an updated version of Steam, too. is a senior reporter ...

Bolt Biotherapeutics has halved its workforce for the second time in two years as the oncology biotech delays a readout of its lead immunotherapy. The company had previously been expecting initial ...